Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017
Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation
STAMFORD, Conn., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at ANESTHESIOLOGY® 2017, the American Society of Anesthesiologists’ annual meeting, to be held October 21-25, 2017 in Boston.
Presentations will include clinical trial data for CR845, Cara’s first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
Details for the presentations are as follows:
| CR845 Oral Abstract Presentation: | |
| Title: | "Respiratory Effects of I.V. CR845: A Peripherally Acting, Selective Kappa Opioid Receptor Agonist” |
| Abstract Number: | JS01 |
| Date / Time: | Sunday, October 22, 2017; 9:00 a.m. – 12:00 p.m. ET |
| Presenter: | Eugene Viscusi, M.D., Director, Acute Pain Management, Thomas Jefferson University |
| Satellite Symposium: | |
| Title: | "A Potential New Path to Pain Relief: Multimodal Analgesia for Enhanced Recovery with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)” |
| Date / Time: | Sunday, October 22, 2017; 7:00 – 8:00 a.m. ET |
| Presenters: | Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics |
| Christopher L. Wu, M.D., Professor, Division of Obstetric Anesthesiology, Division of Regional Anesthesia and Acute Pain Medicine, Department of Anesthesiology, The Johns Hopkins Hospital | |
For information about ANESTHESIOLOGY® 2017, visit www.asahq.org/annualmeeting.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
